Literature DB >> 28221110

Likely Autochthonous Transmission of Trypanosoma cruzi to Humans, South Central Texas, USA.

Sarah M Gunter, Kristy O Murray, Rodion Gorchakov, Rachel Beddard, Susan N Rossmann, Susan P Montgomery, Hilda Rivera, Eric L Brown, David Aguilar, Lawrence E Widman, Melissa N Garcia.   

Abstract

Chagas disease, caused by Trypanosoma cruzi, is a major neglected tropical disease affecting the Americas. The epidemiology of this disease in the United States is incomplete. We report evidence of likely autochthonous vectorborne transmission of T. cruzi and health outcomes in T. cruzi-seropositive blood donors in south central Texas, USA.

Entities:  

Keywords:  Chagas disease; Texas; Trypanosoma cruzi; United States; autochthonous transmission; blood donors; humans; parasites

Mesh:

Year:  2017        PMID: 28221110      PMCID: PMC5382766          DOI: 10.3201/eid2303.161157

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Chagas disease (Trypanosoma cruzi infection) is a neglected tropical disease affecting the Americas and a major cause of preventable illness and death, with ≈6–8 million cases worldwide (). This disease can cause progressive cardiac damage postinfection in 30% of infected persons without any initial suggestive clinical symptoms. These latent infections can remain quiescent for decades before manifesting as cardiac complications, including cardiomyopathy, heart failure, and rare cardiac arrest (). In 2010, US Food and Drug Administration (Sil-ver Springs, MD, USA) issued final guidelines regard-ing screening of the US blood supply for T. cruzi (,). During 2008–2012, screening results showed that 1 in 6,500 donors from an area covering most of the state of Texas were reactive for T. cruzi antibodies (). The origin of infection for these donors was unknown. How-ever, high infection rates for reservoir animals and triato-mine bug vectors in south central Texas suggested that T. cruzi transmission cycles resulting in human infections could occur at a higher frequency than suspected (,). Therefore, we evaluated potential transmission sources and cardiac health of blood donors from south central Texas with T. cruzi antibodies.

The Study

This study was approved by institutional review boards at Baylor College of Medicine (Houston, TX, USA), the Gulf Coast Regional Blood Center (Houston), and the South Texas Tissue and Blood Center (San Antonio, TX, USA). Blood donors residing in the greater San Antonio, Texas, area who had T. cruzi antibodies detected by PRISM Chemiluminescent Immunoassay (Abbott Laboratories, Chicago, IL, USA) or Ortho T. cruzi ELISA (Ortho-Clinical Diagnostics Inc., Raritan, NJ, USA), and a positive result for a Radioimmune Precipitation Assay (Quest Diagnostic Laboratories, Madison, NJ, USA) or an ESA Chagas Test (Abbott Laboratories) during January 1, 2008–December 31, 2014, were invited to participate in the study. Persons previously enrolled in a Houston-based T. cruzi–seropositive blood donor project were not eligible for this study (). Letters in English and Spanish were sent to donors who had T. cruzi antibodies by the blood centers for this study. Those who agreed to participate provided informed consent. We performed 3 procedures: 1) blood collection for additional serologic screening, 2) structured interview to assess potential transmission sources and health, and 3) 12-lead resting electrocardiogram (ECG) (). Blood specimens were used for serologic testing (Table 1). We defined a case of T. cruzi infection if donor screening test results and >2 serologic test results were positive. Likely autochthonous T. cruzi infection was defined in a case-patient who had no major travel to a Latin American country (lasting >2 weeks or that included an overnight stay in a rural region), not having been born in Latin America, and not having a mother born in Latin America (,–). Congenital transmission from a maternal grandmother (2 contiguous congenital infections) cannot be ruled out with this case definition but is unlikely given the low risk for congenital transmission (). Occupations, residential history, and clinical health information were reviewed in a questionnaire. ECG readings were interpreted by a board-certified cardiologist.
Table 1

Characteristics for 14 blood donors infected with Trypanosoma cruzi, south central Texas*

Donor no./age, y/sex
Likely autochthonous transmission†
Blood bank serologic test results‡

Study serologic test results§
ECG results¶
Concurent condition
PRISM or ORTHO
RIPA or ESA
Hemagen
Stat-Pak
DPP
EIA
TESA
1/83/M Yes+++++++Primary AV block, atypical incomplete right BBB, lateral asymmetric T inversionNone
2/61/FYes+++++++Inferolateral asymmetric T inversionHypertension
3/71/MYes+++++++LAD, nonspecific ST/T wave abnormalityKidney failure, hypertension
5/19/MYes+++++++NormalNone
6/60/MYes+++++++Primary AV blockDiabetes, hypertension
7/56/FYes++++++Minimum voltage criteria for LVHNone
8/52/MYes+++++++LADParkinson’s disease
9/25/FYes+++++++NormalNone
10/51/FYes+++++Ind+NormalHeart attack
11/52/FYes+++++++NormalNone
12/45/MNo+++++++NormalBorderline diabetes
13/35/FNo+++++++NormalNone
14/34/FNo++Ind++++Nonspecific T wave changeNone

*Demographic information, likely autochthonous transmission, and concurrent conditions were determined through case-patient interview. ECG, electrocardiogam; Ind, indeterminate; +, positive; –, negative. Test results were based on manufacturers’ protocols for serologic testing. 
†Donors listed as showing autochthonous transmission (donors 12–14) reported living in Mexico or Chile. 
‡ESA, Chagas Test (Abbott Laboratories, Chicago, IL, USA); ORTHO, T. cruzi ELISA (Ortho-Clinical Diagnostics Inc., Raritan, NJ, USA); PRISM, Chemiluminescent Immunoassay (Abbott Laboratories); RIPA, radioimmune precipitation assay (Quest Diagnostic Laboratories, Madison, NJ, USA).
§DPP, dual path platform immunochromatographic confirmation assay (Chembio, Medford, NY, USA); EIA, Chagatest recombinant v3.0 enzyme inmmunoassay (Wiener, Rosario, Argentina); Hemagen; Chagas EIA Kit (Hemagen Diagnostics, Inc., Columbia, MD, USA); Stat-Pak, Chagas immunochromatographic sssay (Chembio, Medford, NY, USA); TESA, trypomastigote excreted or secreted antigen immunoblot (bioMérieux, Marcy l’Etoile, France). Hemagen, Stat-Pak, and DPP were performed at Baylor College of Medicine, (Houston, TX, USA), and EIA and TESA were performed at the Centers for Disease Control and Prevention (Atlanta, GA, USA). 
¶Results were determined from readout of a resting 12-lead ECG and interpreted by a board-certified cardiologist. AV, atrioventricular; LAD, left axis deviation; LVH, left ventricular hypertrophy; RBBB, right bundle branch block.

*Demographic information, likely autochthonous transmission, and concurrent conditions were determined through case-patient interview. ECG, electrocardiogam; Ind, indeterminate; +, positive; –, negative. Test results were based on manufacturers’ protocols for serologic testing. 
†Donors listed as showing autochthonous transmission (donors 12–14) reported living in Mexico or Chile. 
‡ESA, Chagas Test (Abbott Laboratories, Chicago, IL, USA); ORTHO, T. cruzi ELISA (Ortho-Clinical Diagnostics Inc., Raritan, NJ, USA); PRISM, Chemiluminescent Immunoassay (Abbott Laboratories); RIPA, radioimmune precipitation assay (Quest Diagnostic Laboratories, Madison, NJ, USA).
§DPP, dual path platform immunochromatographic confirmation assay (Chembio, Medford, NY, USA); EIA, Chagatest recombinant v3.0 enzyme inmmunoassay (Wiener, Rosario, Argentina); Hemagen; Chagas EIA Kit (Hemagen Diagnostics, Inc., Columbia, MD, USA); Stat-Pak, Chagas immunochromatographic sssay (Chembio, Medford, NY, USA); TESA, trypomastigote excreted or secreted antigen immunoblot (bioMérieux, Marcy l’Etoile, France). Hemagen, Stat-Pak, and DPP were performed at Baylor College of Medicine, (Houston, TX, USA), and EIA and TESA were performed at the Centers for Disease Control and Prevention (Atlanta, GA, USA). 
¶Results were determined from readout of a resting 12-lead ECG and interpreted by a board-certified cardiologist. AV, atrioventricular; LAD, left axis deviation; LVH, left ventricular hypertrophy; RBBB, right bundle branch block. For persons who donated blood in the greater San Antonio area during the study period, we found that 61/256,801 donors had positive serologic results for T. cruzi infection (1/4,200 donors had positive serologic results for T. cruzi infection by 2 assays). Seventeen (28%) of these were enrolled in the study; additional serologic testing confirmed that 14 had antibodies against T. cruzi when the study began (Table 1). These persons had a mean age of 47 years (range 19–83 years); 50% were Hispanic, 50% were non-Hispanic white, and 50% were men. For 3 persons whose blood donor testing results were not confirmed by further serologic testing, 2 were non-Hispanic and 1 was Hispanic (2 women and 1 man); mean age was 51 years. Because of the blinded nature of study recruitment, we cannot identify demographic data for persons who received the letter and chose not to participate. Likely autochthonous transmission of T. cruzi was suspected for 11 (79%) of 14 persons, as defined by study criteria. These 11 persons had a mean age of 50 years; 7 were non-Hispanic whites, and 6 were men. Remaining data presented will concern only the 11 newly identified persons with likely autochthonous infections. A structured interview adapted from a questionnaire used by the Centers for Disease Control and Prevention (Atlanta, GA, USA), the American Red Cross (Washington, DC, USA), and Blood Systems, Inc. (Scottsdale, AZ, USA), was used to identify risk factors for T. cruzi infection (). Because of the lifelong nature of infection and antibody-based diagnostics used, a specific time of infection could not be established for each case-patient. However, we identified common themes for transmission risks for this cohort. Most (91%) case-patients with likely autochthonous infection reported a history of living in a rural community (Figure). Residence in rural communities could pose a risk for T. cruzi transmission because this setting might lead to close proximity with sylvatic transmission cycles involving the vector and infected animals ().
Figure

Current and previous residences of persons with likely autochthonous infection with Trypanosoma cruzi, south central Texas, USA, including 11 autochthonous donors with current residence and birthplace. County boundaries are shown. Previous residences in Texas were chosen if the case-patient reported living in the location >5 years.

Current and previous residences of persons with likely autochthonous infection with Trypanosoma cruzi, south central Texas, USA, including 11 autochthonous donors with current residence and birthplace. County boundaries are shown. Previous residences in Texas were chosen if the case-patient reported living in the location >5 years. Although recreational activities or occupations associated with outdoor exposure were reported among our cohort, we obtained evidence suggesting that opportunities for transmission might be occurring near homes in rural communities (Table 2). Specifically, patients with likely autochthonous infections reported seeing the vector around their current or previous residence (36%), and had animal housing near their homes (73%). An extensive history of outdoor recreational activities of hunting and camping, which has been suggested as a high-risk activity for T. cruzi transmission in the southern United States, was less common then expected (36%) (,). Two of 11 case-patients reported agricultural jobs and staying in substandard housing during the harvest season, thereby introducing the potential for disease transmission from triatomines in the home.
Table 2

High-risk activity profile for 11 case-patients with likely autochthonous infection with Trypanosoma cruzi, south central Texas, USA*

Case-patientBirthplace/former residenceCurrent residenceOccupationalRecreational campingRecreational hunting
1+++++++++
2+++00+0
3+++++++
4000++0
5+++0++0
6+++++++0++
7++++++++0
8++0++0++
90++++00
10++000
11 +++++0+0

*Risk was determined through administration of a patient survey. No risk (0) was defined as not living in a rural area and having no history of outdoor occupation or recreational activities. Low risk (+) was defined as ever living in a rural area, having an outdoor occupation, or engaging in hunting or camping in an area with known triatomine activity. Moderate risk (++) was defined as, in addition to low-risk activities, an extensive history of these activities (>1 y), or having slept in a tent in a rural part of Texas. High risk (+++) was defined as, in addition to moderate-risk activities, reporting 1 of the following: reported seeing triatomines, had collective animal housing around the property, or lived or slept in substandard housing.

*Risk was determined through administration of a patient survey. No risk (0) was defined as not living in a rural area and having no history of outdoor occupation or recreational activities. Low risk (+) was defined as ever living in a rural area, having an outdoor occupation, or engaging in hunting or camping in an area with known triatomine activity. Moderate risk (++) was defined as, in addition to low-risk activities, an extensive history of these activities (>1 y), or having slept in a tent in a rural part of Texas. High risk (+++) was defined as, in addition to moderate-risk activities, reporting 1 of the following: reported seeing triatomines, had collective animal housing around the property, or lived or slept in substandard housing. Five case-patients reported a lack of knowledge of Chagas disease by their primary care physicians. Some case-patients were provided with misinformation, reporting having been told that their screening test result must be false positive because they had no travel history. Furthermore, only 2 case-patients were offered treatment before enrollment in the study. One case-patient reported that, despite seeking treatment for >1 year, he was unable to find a physician able and willing to help. This finding is particularly problematic given that a large proportion (6 of 11) of this cohort had abnormal ECG readings possibly attributable to Chagasic cardiac disease. Although precise cardiac etiologies could not be determined, prevalence of ECG abnormalities was higher than that for population-based studies (,); common findings included atrioventricular block and left axis deviation (Table 1). A previous report also highlighted the same lack of physician awareness of Chagas disease in Texas, despite patients having positive serologic screening results and cardiac manifestations ().

Conclusions

Given the low level of participation of seropositive blood donors, results of this study are limited to persons who participated and might not represent the larger Texas blood donor population or general population. Also, because a 7-year span separated initial screening and enrollment in this study, it is difficult to identify why 3 persons who were initially positive by blood bank screening had discordant results during the study. At follow-up, participating persons were tested with available Centers for Disease Control and Prevention assays, Food and Drug Administration–approved screening, or supplemental tests. Our study adds 11 cases of likely domestically acquired T. cruzi infection to the increasing body of evidence for autochthonous Chagas disease transmission in the southern United States. Combined with previous studies indicating a high rate of T. cruzi infection in triatomine vectors and mammalian reservoirs in this area, our study shows that south central Texas could be a focal point for endemic disease transmission (,). We also identified a major knowledge gap for Chagas disease, which highlights the need for enhanced public health campaigns targeting clinicians and the general population in south central Texas.
  13 in total

1.  The United States Trypanosoma cruzi Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors.

Authors:  Paul T Cantey; Susan L Stramer; Rebecca L Townsend; Hany Kamel; Karen Ofafa; Charles W Todd; Mary Currier; Sheryl Hand; Wendy Varnado; Ellen Dotson; Chris Hall; Pamela L Jett; Susan P Montgomery
Journal:  Transfusion       Date:  2012-03-08       Impact factor: 3.157

Review 2.  Trypanosoma cruzi and Chagas' Disease in the United States.

Authors:  Caryn Bern; Sonia Kjos; Michael J Yabsley; Susan P Montgomery
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

3.  Prevalences of ECG findings in large population based samples of men and women.

Authors:  D De Bacquer; G De Backer; M Kornitzer
Journal:  Heart       Date:  2000-12       Impact factor: 5.994

4.  Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors.

Authors:  D A Leiby; E J Read; B A Lenes; A J Yund; R J Stumpf; L V Kirchhoff; R Y Dodd
Journal:  J Infect Dis       Date:  1997-10       Impact factor: 5.226

5.  Chagas disease risk in Texas.

Authors:  Sahotra Sarkar; Stavana E Strutz; David M Frank; Chissa-Louise Rivaldi; Blake Sissel; Victor Sánchez-Cordero
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

6.  Trypanosoma cruzi screening in Texas blood donors, 2008-2012.

Authors:  M N Garcia; L Woc-Colburn; S N Rossmann; R L Townsend; S L Stramer; M Bravo; H Kamel; R Beddard; M Townsend; R Oldham; M E Bottazzi; P J Hotez; K O Murray
Journal:  Epidemiol Infect       Date:  2014-08-29       Impact factor: 2.451

7.  Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors.

Authors:  Ester C Sabino; Antonio L Ribeiro; Vera M C Salemi; Claudia Di Lorenzo Oliveira; Andre P Antunes; Marcia M Menezes; Barbara M Ianni; Luciano Nastari; Fabio Fernandes; Giuseppina M Patavino; Vandana Sachdev; Ligia Capuani; Cesar de Almeida-Neto; Danielle M Carrick; David Wright; Katherine Kavounis; Thelma T Goncalez; Anna Barbara Carneiro-Proietti; Brian Custer; Michael P Busch; Edward L Murphy
Journal:  Circulation       Date:  2013-02-07       Impact factor: 29.690

8.  Identification of bloodmeal sources and Trypanosoma cruzi infection in triatomine bugs (Hemiptera: Reduviidae) from residential settings in Texas, the United States.

Authors:  Sonia A Kjos; Paula L Marcet; Michael J Yabsley; Uriel Kitron; Karen F Snowden; Kathleen S Logan; John C Barnes; Ellen M Dotson
Journal:  J Med Entomol       Date:  2013-09       Impact factor: 2.278

9.  Electrocardiographic abnormalities in Trypanosoma cruzi seropositive and seronegative former blood donors.

Authors:  Antonio L Ribeiro; Ester C Sabino; Milena S Marcolino; Vera M C Salemi; Barbara M Ianni; Fábio Fernandes; Luciano Nastari; André Antunes; Márcia Menezes; Cláudia Di Lorenzo Oliveira; Vandana Sachdev; Danielle M Carrick; Michael P Busch; Eduard L Murphy
Journal:  PLoS Negl Trop Dis       Date:  2013-02-28

10.  Potential novel risk factors for autochthonous and sylvatic transmission of human Chagas disease in the United States.

Authors:  Melissa N Garcia; Peter J Hotez; Kristy O Murray
Journal:  Parasit Vectors       Date:  2014-07-04       Impact factor: 3.876

View more
  16 in total

1.  Identification of Triatomines and Their Habitats in a Highly Developed Urban Environment.

Authors:  Kyndall C Dye-Braumuller; Rodion Gorchakov; Sarah M Gunter; David H Nielsen; Walter D Roachell; Anna Wheless; Mustapha Debboun; Kristy O Murray; Melissa S Nolan
Journal:  Vector Borne Zoonotic Dis       Date:  2018-12-20       Impact factor: 2.133

2.  Identification of White-tailed Deer ( Odocoileus virginianus) as a Novel Reservoir Species for Trypanosoma cruzi in Texas, USA.

Authors:  Sarah M Gunter; Connor Cordray; Rodion Gorchakov; Ina Du; Bob Dittmar; Eric L Brown; Kristy O Murray; Melissa S Nolan
Journal:  J Wildl Dis       Date:  2018-06-11       Impact factor: 1.535

Review 3.  Chagas Disease in the United States: a Public Health Approach.

Authors:  Caryn Bern; Louisa A Messenger; Jeffrey D Whitman; James H Maguire
Journal:  Clin Microbiol Rev       Date:  2019-11-27       Impact factor: 26.132

Review 4.  Diagnosis and Management of Chagas Cardiomyopathy in the United States.

Authors:  Lillian Benck; Evan Kransdorf; Jignesh Patel
Journal:  Curr Cardiol Rep       Date:  2018-10-11       Impact factor: 2.931

5.  Chagas Disease Knowledge and Risk Behaviors of the Homeless Population in Houston, TX.

Authors:  Alexandra Ingber; Melissa N Garcia; Juan Leon; Kristy O Murray
Journal:  J Racial Ethn Health Disparities       Date:  2017-05-31

6.  Autochthonous Chagas Disease in the United States: How Are People Getting Infected?

Authors:  Norman L Beatty; Stephen A Klotz
Journal:  Am J Trop Med Hyg       Date:  2020-09       Impact factor: 2.345

7.  Prevalence and Seroprevalence of Trypanosoma cruzi Infection in a Military Population in Texas.

Authors:  Bryant J Webber; Mary T Pawlak; Sandra Valtier; Candelaria C Daniels; Charla C Tully; Edward J Wozniak; Walter D Roachell; Francisco X Sanchez; Audra A Blasi; Thomas L Cropper
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

8.  Microbiomes of North American Triatominae: The Grounds for Chagas Disease Epidemiology.

Authors:  Sonia M Rodríguez-Ruano; Veronika Škochová; Ryan O M Rego; Justin O Schmidt; Walter Roachell; Václav Hypša; Eva Nováková
Journal:  Front Microbiol       Date:  2018-06-13       Impact factor: 5.640

9.  Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B supertypes in Chagasic chronic patients from Mexico.

Authors:  Liliana E Villanueva-Lizama; Julio V Cruz-Chan; Amarú Del C Aguilar-Cetina; Luis F Herrera-Sanchez; Jose M Rodriguez-Perez; Miguel E Rosado-Vallado; Maria J Ramirez-Sierra; Jaime Ortega-Lopez; Kathryn Jones; Peter Hotez; Maria Elena Bottazzi; Eric Dumonteil
Journal:  PLoS Negl Trop Dis       Date:  2018-01-29

Review 10.  The effects of climate change on infectious diseases with cutaneous manifestations.

Authors:  Sarah J Coates; Scott A Norton
Journal:  Int J Womens Dermatol       Date:  2020-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.